INTRODUCTION
High-risk neuroblastoma (HR-NBL) is characterised by poor long-term survival, and represents a major clinical challenge in paediatric oncology. The major role of high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) has been reported in three randomised studies. [1] [2] [3] [4] [5] The positive impact of the busulfan (Bu) and melphalan (Mel) combination on survival, initially shown by the Gustave Roussy experience, 6 has now been demonstrated in the International Society of Paediatric Oncology European Neuroblastoma Network (SIOPEN)/HR-NBL1 randomised study. 7 Several studies have identified age at diagnosis and the response of metastases at the end of induction therapy as major prognostic factors (Ladenstein R, ANR2014-POC046). 6, [8] [9] [10] On the basis of these data, we defined a very high-risk (VHR) population to be treated using a new strategy based on the concept of dose intensity. We reported the results of the first cohort of patients with VHR-NBL treated with double-tandem HDC combining thiotepa and busulfan-melphalan (Bu-Mel) followed by ASCT. These results provided the rationale for exploring this strategy in the upcoming SIOPEN VHR protocol.
SUBJECTS AND METHODS
The data of patients receiving HDC and ASCT in the transplantation unit of the Paediatric and Adolescent Oncology Department at Gustave Roussy were prospectively recorded in the Gustave Roussy Paediatric ASCT database. The present study analysed data from all the patients with a VHR-NBL and treated with double-tandem HDC combining thiotepa and Bu-Mel followed by ASCT registered in this database until August 2011. The parents/guardians gave their written informed consent for the treatment and the retrospective analysis of clinical data according to the Institutional Review Board of the Gustave Roussy.
Subjects
VHR criteria were defined as follows: stage 4 NBL at diagnosis or relapse, age41 year at diagnosis, less than a partial response (PR) of metastases (decreaseo50% of the number of metastatic sites) and more than three metaiodobenzylguanidine (mIBG) spots after two lines of conventional chemotherapy in patients o10 years old or no complete response (CR) of metastases after one line of conventional chemotherapy in patients 410 years old. The exclusion criteria were progressive disease (PD) at the time of HDC, visceral failure, suboptimal PBSC mobilisation and no informed consent.
High-dose chemotherapy
The first HDC course comprised of thiotepa 300 mg/m 2 per dose on 3 consecutive days in a 2-h infusion up to a total dose of 900 mg/m 2 . Oral Bu was used until 2006 (150 mg/m 2 on 4 consecutive days in four equal doses), 11 after which the IV route with Busilvex (0.8-1.2 mg/kg per dose according to patient weight up to a total of 16 doses) was introduced. 12, 13 After a 24-h interval, a single dose of Mel (140 mg/m 2 ) was administered.
Supportive care
Clonazepam was administered as prophylaxis against seizures during Bu administration. 15 G-CSF at a dose of 5 μg/kg per day was administered after each course from day 5 post-ASCT until stable neutrophil recovery (4500/mm 3 ). 16 RBCs were transfused when the haemoglobin level was below 8 g/dL. Platelets were transfused to maintain a platelet count above 20 × 10 9 /L or to control bleeding. All blood products were irradiated (25 Gy). Defibrotide was administered (25 mg/kg per day IV in four doses) as prophylaxis against sinusoidal obstruction syndrome (SOS) since 2006. 17 Acyclovir prophylaxis was not administered (Guerrini-Rousseau L, SIOP meeting 2014; P-0158). All patients received trimethoprim-sulfamethoxazole as prophylaxis against Pneumocystis jiroveci.
Evaluation of toxicity
Toxicity was evaluated according to Bearman's grading system. 18 Other treatments
In cases of surgical risk, resection of the primary tumour was postponed until after HDC. Radiotherapy was performed as a complementary local treatment at a dose of 21 Gy. Maintenance treatment comprised six courses of retinoic acid (160 mg/m 2 per day × 14 days) with a 14-day rest interval between the two courses.
Assessment of disease extent and tumour response
Tumour response was evaluated after each course of HDC and at the end of treatment. The primary tumour was evaluated by computed tomography or magnetic resonance imaging. Disease extent was assessed by mIBG scan using the SIOPEN scoring system. 19 Two biopsies and four aspirates were obtained for morphological evaluation of bone marrow.
Statistical method
The main end point was event-free survival (EFS), defined as the interval from the diagnosis to the first event (progression, relapse, secondary malignancy or death, whatever the cause) or to the date of the last followup visit for those with no event. The secondary end point was overall survival (OS), defined as the interval from the diagnosis to the time of death, and toxicity. Survival curves were estimated using the Kaplan-Meier method, with Rothman's 95% confidence intervals. 20 Median follow-up was estimated using Schemper's method. 21 
RESULTS

Patient characteristics
From April 2004 to August 2011, 26 patients with VHR-NBL were eligible for the tandem HDC strategy. Patient characteristics at diagnosis are described in Table 1 . Their median age at diagnosis was 4.4 years (range 1-15.9 years), and the male to female ratio was 12:14. The primary tumour was abdominal and thoracic in 24 and 2 patients, respectively. All but four had a stage 4 NBL according to the Revised International Neuroblastoma Diagnosis and Staging Criteria. 22 Among them, MYCN was amplified in three patients. The bone marrow was involved in 21 patients. The mIBG SIOPEN score was evaluable in 21 patients, with a median score of 22 (range 1-48). Hepatic metastases were found in 5/22 patients, pulmonary metastases in 1/22 and 1 patient had a brain metastasis. Four patients had a stage 3 NBL at diagnosis with a metastatic relapse, 2/4 had a MYCN amplified tumour.
Patient characteristics before HDC are described in Table 2 . They received a median number of five drugs (range 5-8), and three lines of treatment (range 2-5). CR and PR were obtained in 3/26 and 23/26 patients, respectively. The mIBG scan was positive in 18/26 children, with a median SIOPEN score of 2 (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Three patients still exhibited hepatic metastasis, and seven patients had a positive bone marrow biopsy. The median number of CD34+ cells collected per kg/patient was 4.48 × 10 6 (range 2.77-12) and 4.38 × 10 6 (range 3.07-14) for thiotepa and Bu-Mel courses, respectively.
Other treatments The primary tumour was resected before HDC in 14/26 patients and postponed till after HDC in nine patients. Surgery was not performed in three patients (one local CR, one post-HDC toxic death, one PD after HDC). Fifteen patients had complementary radiotherapy of the primary tumour. Radiotherapy was not delivered because of disease progression in three patients, post-HDC toxicity in six patients (SOS, n = 3; digestive toxicity, n = 2; toxic death, n = 1), and parental refusal in two patients. Isolated metastases at the end of the treatment were treated locally in three patients with surgery (mediastinal lymph node, one patient), radiotherapy (bone metastasis, one patient) and radiofrequency (liver metastasis, one patient). Maintenance therapy with oral retinoic acid was administered to 22 patients. It was combined in one patient with antiganglioside-2 antibody in the SIOPEN long-term infusion clinical trial (NCT01701479). One case of S. epidermidis septicaemia occurred. The median duration of antibiotherapy was 15 days (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Viral infections were identified in 7/24 patients (5/7 herpes zoster, 2/7 HSV) after a median interval of 9.8 months (range 1.4-66.2) after ASCT. Extrahaematological toxicity was mainly digestive and hepatic. Grade42 mucositis, lasting a median duration of 9 days (range 1-29), was documented in 10/24 patients. Gradep2 diarrhoea was reported in 14/24 patients, whereas grade42 occurred in two patients. Grade42 vomiting occurred in only one child. SOS was diagnosed in 11/24, 7/11 and 4/11 patients who received or not a defibrotide prophylaxis, respectively. A grade42 SOS was observed in six cases (25%) with a median duration of 11 days (range 3-40). The only SOS-related death occurred 2 months after HDC in a patient who received a curative defibrotide treatment. Grade 2 skin toxicity with hyperpigmentation and dryness was reported in 5/24 patients and grade42 toxicity (skin ulcerations) in 3/24 cases. One child experienced neurological toxicity with dizziness and transient facial nerve paralysis during chemotherapy. The median hospital stay was 26 days (range 16-55).
Tumour response After HD thiotepa 4/26 patients were in CR, 12 achieved a PR, 6 had stable disease and 2 patients were not evaluated. Two patients experienced PD and did not receive the Bu-Mel HDC. The median mIBG SIOPEN score was 2 (range 0-20). Tumour response evaluated after Bu-Mel in 23/24 patients was as follows: 6 CR, 7 PR, Tandem high-dose chemotherapy in very high-risk neuroblastoma C Pasqualini et al 10 SD (Figure 1) . The median mIBG SIOPEN score was 1 (range 0-20). The 3-year EFS and OS rates (±95% confidence interval) after the diagnosis were 37.3% (21.3-56.7%) and 69.0% (49.7-83.4%), respectively ( Figure 2 ). All four patients with stage 3 disease at diagnosis died of PD. Ten patients were alive at the last follow-up (January 2015), with a median follow-up of 3.9 years (range 3.2-7.2). No significant prognostic factor (age, sex, SIOPEN score at diagnosis, post-induction and post-thiotepa tumour status) was identified in our population.
DISCUSSION
The improvement of the prognosis in patients with HR-NBL observed over the last three decades is related to the intensification of induction therapy, HDC and better supportive care. 1 Three randomised studies have demonstrated the major role of HDC in HR-NBL. [1] [2] [3] [4] [5] The randomised trial conducted by the Children's Cancer Group reported significantly better 5-year EFS following HDC with a purged autologous bone marrow transplant than with non-HDC (30 ± 4% vs 19 ± 3%, respectively), although improvement of OS was not statistically significant. 1 The response of metastases to induction chemotherapy has been demonstrated to be a significant prognostic factor in HR-NBL. 6, [8] [9] [10] 23 Recently, in the French cohort of patients with metastases treated with the N7 induction chemotherapy followed by HD Bu-Mel and ASCT, 8-year EFS of patients with a CR of metastases at the end of induction therapy was 52% vs 19% for the patients without a CR of metastases (HR of failure = 0.42; P = 0.02). 8 A positive mIBG score after induction is also a prognostic factor in HR-NBL. 10, 23 Age at diagnosis has proved to be a major prognostic factor. 6 Previously reported data suggested that patients 410 years old at diagnosis with stage 4 NBL had very poor outcome in spite of intensive treatment. 24 On the basis of these results, we identified a VHR-NBL population characterised by stage 4 NBL at diagnosis or relapse, age 41 year at diagnosis, less than a PR of metastases and more than 3 mIBG spots after 2 lines of conventional chemotherapy in patients o 10 years old, or no CR of metastases after 1 line of conventional chemotherapy in patients 410 years old. More recently, the analysis of the HR-NBL1/SIOPEN cohort showed that the age cutoff is lower than the one used to stratify patients in our study, with a 5-year EFS of 0.15 ± 0.02 and 0.30 ± 0.02 in patients 45 years and between 1.5 and 5 years, respectively (Ladenstein R, ANR2014-POC046).
A strategy based on tandem HDC followed by ASCT was proposed to evaluate the impact of intensified consolidation therapy in these VHR-NBL patients. PBSC mobilisation allowed us to collect a high number of haematological stem cells and to administer two courses of HDC with rapid haematological recovery, leading to a dose intensity-based treatment. 25 The choice of thiotepa and Bu-Mel was based on previous studies of HDC in NBL. 6, 7, [26] [27] [28] [29] The benefit linked to the administration of Bu-Mel was recently confirmed in the randomised HR-NBL-1/ SIOPEN trial comparing Bu-Mel to HD carboplatin, etoposide and Mel (CEM), with a 3-year EFS rate of 49% and 33%, respectively (P o 0.001). 7 In this VHR population, the 3-year EFS and OS rates of 37.3% (21.3-56.7%) and 69.0% (49.7-83.4%) appeared very encouraging compared with previously reported data. 6, 9, 26, 27 However, the cohort is too small to allow definitive conclusions.
The toxicity of this intensified treatment was manageable. Whereas the duration of neutropenia was similar after both HDC regimens, the duration of thrombocytopenia was significantly longer after Bu-Mel than after thiotepa despite a similar number of infused CD34+ cells/kg. This difference can be explained by the peripheral thrombocytopenia related to SOS after Bu-Mel. As anticipated, the cumulative visceral toxicity of alkylating agents induced a higher rate and severity of toxicity in comparison with that observed with Bu-Mel in a single HDC course (ProustHoudemont S, ANR2010-SEL15). The most frequent nonhaematological toxicities were mucositis and liver toxicity. The higher incidence of grade 42 SOS (25%) was manageable with adapted supportive care. The mortality rate was below that currently accepted in international protocols for HR-NBL.
Different studies have demonstrated encouraging results with triple/double transplantation followed by ASCT in HR-NBL. [30] [31] [32] [33] [34] A phase III study comparing two different consolidation strategies (CEM vs CEM followed by HD thiotepa-cyclophosphamide) with ASCT in HR-NBL patients has been ruled out by the COG [NCT00567567].
In refractory or relapsed NBL, 131 I-mIBG has been safely used as a single agent and combined with conventional chemotherapy, with response (CR+PR) achieved in 2/20 (10%) and 9/32 (28%) patients, respectively.
35,36 131 I-mIBG was combined with topotecan in refractory/relapsed HR-NBL, with acceptable morbidity and mortality profiles, and with 3-year EFS and OS rates of 16 ± 5% and 26 ± 6% for the entire cohort (Gaze M, ANR2012-OR79). Two studies reported the safety and the efficacy of 131 I-mIBG used as consolidation therapy followed by Bu-Mel and ASCT in refractory metastatic NBL, with response achieved in 5/8 and 1/7 patients 37 (Defachelles AS, SIOP2014-P160). The activity and toxicity of 131 I-mIBG when combined with CEM and ASCT have been investigated in a phase II multicentre study, responses were observed in 4/41 (10%) evaluable patients with primary refractory or PD, and the 3-year EFS and OS rates after ASCT were 20 ± 7% and 62 ± 8%, respectively. 38 The results of these studies provided a good rationale for evaluating and comparing the safety and efficacy in a homogeneous cohort of this intensified consolidation in VHR patients. The current international collaborations aiming at identifying VHR patients at diagnosis will help to propose early adapted strategies in the future. In the upcoming SIOPEN VHR-NBL protocol, patients with VHR-NBL will be randomised to receive either tandem HDC comprising thiotepa and Bu-Mel courses, or 131 I-mIBG and Bu-Mel, followed by ASCT. This protocol will evaluate the safety and efficacy of both arms, and define the best consolidation strategy to be further evaluated in patients with HR-NBL.
